Banmeet Anand

Dr. Anand joined Harpoon in March 2022 as Senior Vice President of Translational Medicine with more than 18 years of experience in the discovery and development of antibodies (naked, ADCs and bi-specific), small molecules, and cellular therapies (NK-T, CAR-T). Dr. Anand most recently was Vice President of non-clinical development at Molecular Templates where he led toxicology, pharmacology, non-clinical/clinical PK/PD, IND-enabling studies supporting translational research and clinical programs for immunotoxins. Dr. Anand previously held management and scientific positions at NantKwest, Astellas (Agensys) and Genentech where he was involved in early and late development of multiple approved drugs such as RITUXAN®, PADCEV® and OCREVUS®. Dr. Anand received his PhD in Pharmaceutical Sciences and Chemistry from the University of Missouri-Kansas City.